Mary Alikian

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi et al. · Blood · 2012 · 218 citations · Full text

A Novel Pyrazolo[1,5-<i>a</i>]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration

Dean A. Heathcote, Hetal Patel, Sebastian H. B. Kroll et al. · Journal of Medicinal Chemistry · 2010 · 99 citations · Full text

Mutational landscape of B‐cell post‐transplant lymphoproliferative disorders

Thomas Menter, Darius Juškevičius, Mary Alikian et al. · British Journal of Haematology · 2017 · 80 citations · Full text

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia

Mary Alikian, Alexandra S. Whale, Susanna Akiki et al. · Clinical Chemistry · 2016 · 75 citations

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors

Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani et al. · Haematologica · 2019 · 57 citations · Full text